Distribusion Technologies | $80,000,000 | (Sep 27, 2024)
Cytix | $2,143,528 | (Sep 27, 2024)
Convergence | $12,000,000 | (Sep 27, 2024)
EverImmune
France
- Villejuif
- 19/09/2023
- Unknown
- $3,410,000
EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology.
It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients.
The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in its pipeline for use in the treatment of different types of cancer.
Established in 2016, by co-founders Pr. Laurence Zitvogel and Dr. Romain Daillere, everImmune is a spinoff from Gustave Roussy (Paris, France). The company is part of ONCOBIOME, the first European program dedicated to microbiome and cancer, funded by the European Union.
- Industry Research Services
- Website https://www.everimmune.com/
- LinkedIn https://www.linkedin.com/company/everimmune/about/
Related People
Romain DaillèreCo Founder
France -
ND
Engineer in Biotechnology, PhD in Immuno-oncology. Scientific co-founder of EverImmune, a spin-off biotech. company from Gustave Roussy Transfer, devoted to treating cancer patients with live biotherapeutic products for oral adjuvants to anticancer treatments. Driven by the desire to translate discoveries and innovations from bench to bedside. Strong scientific background with pioneer publications in high-impact factor journals and patents. Leadership and team management spirit. Focusing on excellence in science.
SURGAR | $12,288,870 | (Sep 27, 2024)
Quorum | Undisclosed Amount | (Sep 27, 2024)
Prepared | $27,000,000 | (Sep 27, 2024)
AmpUp | $15,000,000 | (Sep 27, 2024)
HighFive | $250,000 | (Sep 27, 2024)
Tetrix | $5,000,000 | (Sep 27, 2024)
The Curling Group | $5,000,000 | (Sep 27, 2024)
AminoChain | $5,000,000 | (Sep 27, 2024)
Gladly | $40,000,000 | (Sep 27, 2024)